Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 115 participants.

Also called NCT07807384

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 115 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07807384
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07807384. Allocation not applicable; no masking; primary purpose treatment. Start 2026-11 (anticipated); primary completion 2029-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Condition
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Intervention (Drug)
Mavacamten
Lead sponsor
Second Affiliated Hospital of Nanchang University (class: other)

Record details

Record id
cardio:ct-nct07807384
Content hash
c50541e08915a0240edd2b85df84196ee190a8c7eebe3e9cb23549192a165bcd